Mutasynthesis of Physostigmines in

Molecular Structure Myxococcus xanthus / chemistry Physostigmine / analogs & derivatives

Journal

Organic letters
ISSN: 1523-7052
Titre abrégé: Org Lett
Pays: United States
ID NLM: 100890393

Informations de publication

Date de publication:
20 08 2021
Historique:
pubmed: 7 8 2021
medline: 20 11 2021
entrez: 6 8 2021
Statut: ppublish

Résumé

The alkaloid physostigmine is an approved anticholinergic drug and an important lead structure for the development of novel therapeutics. Using a complementary approach that merged chemical synthesis with pathway refactoring, we produced a series of physostigmine analogues with altered specificity and toxicity profiles in the heterologous host

Identifiants

DOI: 10.1021/acs.orglett.1c02374 PMID: 34355569
pubmed: 34355569
doi: 10.1021/acs.orglett.1c02374
doi:

Substances chimiques

Physostigmine 9U1VM840SP
phenserine SUE285UG3S

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6563-6567

Auteurs

Lea Winand (L)

Department of Biochemical and Chemical Engineering, TU Dortmund University, Dortmund, 44227 Nordrhein-Westfalen, Germany.

Pascal Schneider (P)

Institute of Bioorganic Chemistry, Heinrich-Heine-University Düsseldorf at Forschungszentrum Jülich, Jülich, 44227 Nordrhein-Westfalen, Germany.

Sebastian Kruth (S)

Department of Biochemical and Chemical Engineering, TU Dortmund University, Dortmund, 44227 Nordrhein-Westfalen, Germany.

Nico-Joel Greven (NJ)

Department of Biochemical and Chemical Engineering, TU Dortmund University, Dortmund, 44227 Nordrhein-Westfalen, Germany.

Wolf Hiller (W)

Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, 44227 Nordrhein-Westfalen, Germany.

Marcel Kaiser (M)

Parasite Chemotherapy Unit, Swiss Tropical and Public Health Institute, 4002 Basel, Switzerland.
University of Basel, 4001 Basel, Switzerland.

Jörg Pietruszka (J)

Institute of Bioorganic Chemistry, Heinrich-Heine-University Düsseldorf at Forschungszentrum Jülich, Jülich, 44227 Nordrhein-Westfalen, Germany.
Institut für Bio- und Geowissenschaften: Biotechnologie (IBG-1), Forschungszentrum Jülich, Jülich, 52428 Nordrhein-Westfalen, Germany.
ORCID: 0000-0002-9819-889X

Markus Nett (M)

Department of Biochemical and Chemical Engineering, TU Dortmund University, Dortmund, 44227 Nordrhein-Westfalen, Germany.
ORCID: 0000-0003-0847-086X

Articles similaires

Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-

Alonzo González-González, Oscar Sánchez-Sánchez, Lilián Yépez-Mulia et al.
1.00
Giardia lamblia Trichomonas vaginalis Entamoeba histolytica Antiprotozoal Agents Quinoxalines

Structural basis for regulation of a CBASS-CRISPR-Cas defense island by a transmembrane anti-σ factor and its ECF σ partner.

Diego Bernal-Bernal, David Pantoja-Uceda, Jorge Pedro López-Alonso et al.
1.00
CRISPR-Cas Systems Sigma Factor Myxococcus xanthus Bacterial Proteins Models, Molecular

Unravelling a diversity of cellular structures and aggregation dynamics during the early development of

Natsuko Rivera-Yoshida, Alejandro V Arzola, Mariana Benítez
1.00
Myxococcus xanthus

Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors.

Xiaorui Han, Pingping Lan, Qianfeng Chen et al.
1.00
Quinoxalines Humans MAP Kinase Kinase Kinase 5 Structure-Activity Relationship Protein Kinase Inhibitors

Classifications MeSH

questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Mutasynthesis of Physostigmines in
questionsmedicales.fr › Bactéries › Proteobacteria › Deltaproteobacteria › Myxococcales › Myxococcus › Myxococcus xanthus › Mutasynthesis of Physostigmines in
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indolizine › Indolizidines › Alcaloïdes indoliques › Physostigmine › Mutasynthesis of Physostigmines in